PMID- 21875466
OWN - NLM
STAT- MEDLINE
DCOM- 20120524
LR  - 20171116
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 33
IP  - 5
DP  - 2011 May
TI  - [Correlation of TOP2A gene expression and survival of breast cancer patients].
PG  - 363-6
AB  - OBJECTIVE: The aim of this study was to assess the TOP2A RNA expression and the 
      relationship of TOP2A protein expression with metastasis-free interval in breast 
      cancer patients. METHODS: TOP2A expression was analyzed prior to surgery in 86 
      patients. The level of TOP2A gene amplification was analyzed by fluorescence in 
      situ hybridization (FISH), its RNA expression level with RT-PCR, and their 
      correlation with TOP2A protein expression was assessed by immunohistochemistry 
      (IHC). The correlation between RNA expression level and metastasis-free interval 
      in breast cancer patients was also analyzed. RESULTS: Aberrations (amplification 
      or deletion) of TOP2A copy number was observed in 25.6% (22/86) of the cases. 
      TOP2A protein expression was detected in 66.3% (57/86) of the samples. There was 
      a significant correlation between the TOP2A RNA expression and protein expression 
      (P < 0.001). TOP2A gene expression was significantly associated with the 
      metastasis-free interval in the breast cancer patients (P = 0.001). There was no 
      significant correlation between TOP2A gene amplification and TOP2A protein 
      expression (P = 0.211). CONCLUSIONS: TOP2A RNA level is an objective and reliable 
      prognostic indicator in breast cancer.
FAU - Meng, Hui
AU  - Meng H
AD  - Department of Oncology, First Affiliated Hospital, Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Li, Wen-cai
AU  - Li WC
FAU - Wang, Liu-xing
AU  - Wang LX
FAU - Li, Wen-bin
AU  - Li WB
FAU - Zhang, Lan
AU  - Zhang L
FAU - Fan, Qing-xia
AU  - Fan QX
FAU - Wang, Rui-lin
AU  - Wang RL
FAU - Lu, Tai-ying
AU  - Lu TY
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Poly-ADP-Ribose Binding Proteins)
RN  - 63231-63-0 (RNA)
RN  - EC 5.99.1.3 (DNA Topoisomerases, Type II)
RN  - EC 5.99.1.3 (TOP2A protein, human)
SB  - IM
MH  - Antigens, Neoplasm/genetics/*metabolism
MH  - Breast Neoplasms/drug therapy/*genetics/metabolism/surgery
MH  - Carcinoma, Ductal, Breast/drug therapy/*genetics/metabolism/surgery
MH  - Carcinoma, Intraductal, Noninfiltrating/drug therapy/genetics/metabolism/surgery
MH  - Carcinoma, Lobular/drug therapy/genetics/metabolism/surgery
MH  - Chemotherapy, Adjuvant
MH  - DNA Topoisomerases, Type II/genetics/*metabolism
MH  - DNA-Binding Proteins/genetics/*metabolism
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Amplification
MH  - Gene Deletion
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Poly-ADP-Ribose Binding Proteins
MH  - RNA/metabolism
MH  - Remission Induction
EDAT- 2011/08/31 06:00
MHDA- 2012/05/25 06:00
CRDT- 2011/08/31 06:00
PHST- 2011/08/31 06:00 [entrez]
PHST- 2011/08/31 06:00 [pubmed]
PHST- 2012/05/25 06:00 [medline]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):363-6.